BPA for pemazyre

Ended Awarded Last action

Contract number
36E79721A0005
Awardee
Awarding agency
Task orders
1 $12,725 obligated

Award facts

Opportunity
  • VA797P12Q0002 Solicitation number
Combined order value
$12,725 Current and potential, with all options
Last date to order 100% complete
IDV ceiling <1% used
$3,750,000.00
Award type
Single award
Who can order
Only the awarding agency
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
Pricing
Firm Fixed Price

Award details come from SAM.gov/FPDS.

About this IDV

This federal contract Indefinite Delivery Vehicle (IDV) is a Blanket Purchase Agreement (BPA) awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Incyte Corporation, a global biopharmaceutical company. The BPA, valued at $3,750,000, is for the supply of Pemazyre (pemigatinib), Incyte's specialized oncology drug used to treat certain types of cancer. The BPA, which runs through November 20, 2025, is issued under Incyte's Federal Supply Schedule (FSS-61-IB) contract for Pharmaceuticals and Drugs, valued at $541 million.

Under this BPA, Incyte will fulfill delivery orders for Pemazyre tablets in 4.5mg, 9mg, and 13.5mg dosages to VA medical centers and facilities across the United States. A sample $12,725.23 task order was awarded to Incyte by the VA's Veterans Integrated Service Network 22 for the delivery of Pemazyre tablets to support healthcare services for veterans within VISN 22's coverage area. All contract awards have been issued as firm fixed price with no set-aside designations, indicating Incyte competes in the unrestricted federal marketplace for these critical pharmaceutical supply contracts.

Task orders

Task order Ordering agency Obligated Awarded
Pemazyre tabs 36C26221N0840 Veterans Integrated Service Network 22 (VHA) $12,725

Transactions

Action Obligated Date
Supplemental Agreement for work within scope P00008 · 2025 public law pricing updates. $0
Exercise an Option P00007 · Exercise option year 4 $0
Supplemental Agreement for work within scope P00006 · 2024 public law pricing updates $0
Exercise an Option P00005 · Exercise option year 3 $0
Supplemental Agreement for work within scope P00004 · 2023 public law pricing updates $0
Exercise an Option P00003 · Exercise the 2ND option year on BPA 36E79721A0005 $0
Supplemental Agreement for work within scope P00002 · 2022 public law pricing updates $0
Exercise an Option P00001 · Exercise option year 1 for pemazyre. $0
Original award $0

Quick answers

Who was awarded contract 36E79721A0005?

36E79721A0005 was awarded to Incyte Corporation by National Acquisition Center (Headquarters) on November 21, 2020.

How much is contract 36E79721A0005 worth?

Orders under 36E79721A0005 have obligated $12,725. 36E79721A0005's own ceiling is $3,750,000.

How many orders have been placed under contract 36E79721A0005?

1 order has been placed under 36E79721A0005, the latest on August 6, 2021.

Who can order from contract 36E79721A0005?

36E79721A0005 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.

Is contract 36E79721A0005 under another contract?

Yes. 36E79721A0005 is a blanket purchase agreement under 36F79720D0189, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).

Was contract 36E79721A0005 competed?

The extent of competition for 36E79721A0005 was full and open competition. The government received 1 offer.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV